Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study

10:08 EDT 14 Jun 2014 | Xconomy

As a gene therapy company, Bluebird Bio was a surprising IPO star in 2013. After all, it’s working in a field that was kicked to the curb in the previous decade. What’s more, it made its IPO pitch on the back of the slimmest amount of data. But d...

Original Article: Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study

NEXT ARTICLE

More From BioPortfolio on "Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Gene Therapy
Latest News Clinical Trials Research Drugs Reports Corporate
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Advertisement